Cisplatin + Durvalumab + Tremelimumab
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oropharyngeal Squamous Cell Carcinoma
Conditions
Oropharyngeal Squamous Cell Carcinoma
Trial Timeline
May 28, 2018 → Jul 31, 2026
NCT ID
NCT03410615About Cisplatin + Durvalumab + Tremelimumab
Cisplatin + Durvalumab + Tremelimumab is a phase 2 stage product being developed by AstraZeneca for Oropharyngeal Squamous Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT03410615. Target conditions include Oropharyngeal Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03410615 | Phase 2 | Active |
Competing Products
12 competing products in Oropharyngeal Squamous Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 33 |
| Cetuximab + Cisplatin | Eli Lilly | Phase 2 | 52 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1/2 | 41 |
| Cisplatin + Durvalumab | AstraZeneca | Phase 3 | 77 |
| Chemoradiotherapy arm + Immunotherapy + Radiotherapy arm | AstraZeneca | Phase 2 | 52 |
| MEDI0457 + Durvalumab | AstraZeneca | Phase 2 | 52 |
| VB10.16 + Pembrolizumab | Merck | Phase 1/2 | 41 |
| Cetuximab | Merck | Phase 2 | 52 |
| 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) | Merck | Phase 3 | 77 |
| Paclitaxel + Carboplatin + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cyclophosphamide + IRX-2 + Nivolumab | Bristol Myers Squibb | Phase 1 | 32 |
| CUE-101 | Cue Biopharma | Phase 2 | 44 |